Drug Database
GE

gemigliptin + metformin hydrochloride (ZemiMet / ZemiMet SR)

✓ Approved

LG Chem Ltd. · DPP4 · Small Molecule

What is gemigliptin + metformin hydrochloride?

gemigliptin + metformin hydrochloride is a small molecule developed by LG Chem Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesZemiMet, ZemiMet SR
CompanyLG Chem Ltd.
Drug ClassSmall Molecule
Molecular TargetDPP4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, LG Chem Ltd.

Mechanism of Action

Molecular Targets

gemigliptin + metformin hydrochloride acts on 1 molecular target:

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

gemigliptin + metformin hydrochloride is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

Related Research Articles

PubMedMolecules (Basel, Switzerland)2026-10-16

A Robust AQbD-Based RP-HPLC Method for Simultaneous Quantification of Acyclovir and Doxepin Hydrochloride in Bulk and Topical Cream Formulation.

Kumar Akshay A, Kumar Mohit M, Saini Abhishek A, Agrawal Mohit M et al.

The present study describes the development and validation of a simple, rapid, and reliable RP-HPLC method for the simultaneous estimation of acyclovir and doxepin hydrochloride in bulk and topical cream formulation using an Analytical Quality by Design (AQbD) approach. The combination of acyclovir, an antiviral agent, and doxepin, an antipruritic and anti-inflammatory drug, offers a combined topical approach for the management of herpes-associated skin conditions. The method development was guided by a predefined Analytical Target Profile (ATP), followed by systematic risk assessment to identify critical quality attributes (CQAs) and critical method parameters (CMPs). The central composite design (CCD) was employed to optimize key chromatographic variables, including mobile phase composition and flow rate. The chromatographic separation was achieved on a C18 column using an isocratic mobile phase of acetonitrile and water (40:60 v/v) at a flow rate of 1.0 mL/min, with UV detection at 240 nm. The retention times were found to be 2.58 min for acyclovir and 4.64 min for doxepin hydrochloride, indicating efficient separation with good peak symmetry. The method was validated according to ICH Q2(R2) guidelines and demonstrated excellent linearity over the concentration ranges of 2-10 µg/mL (acyclovir) and 12-28 µg/mL (doxepin hydrochloride), with correlation coefficients greater than 0.997. The method exhibited high precision (%RSD < 2%), accuracy (recovery within 99-101%), and good sensitivity with low LOD and LOQ values. The robustness studies confirmed the reliability of the method under small, deliberate variations in chromatographic conditions. The developed cream formulation showed uniform drug content and satisfactory in vitro drug release, with a sustained release profile reaching approximately 96% over 24 h. In conclusion, the proposed AQbD-based RP-HPLC method is suitable for routine quantitative analysis and quality control of acyclovir and doxepin hydrochloride in combined topical formulations.

PMID 42883330
Read full article →
PubMedCancers2026-10-16

Metformin as an Adjunct to Fertility-Sparing Treatment in Atypical Endometrial Hyperplasia and Early-Stage Endometrioid Endometrial Cancer: Narrative Review.

Yordanov Angel A, Tsoneva Eva E, Kostov Stoyan S, Yanachkova Vesselina V et al.

Objective: This study aims to evaluate the potential role of metformin as an adjunct to fertility-sparing treatment strategies for women with atypical endometrial hyperplasia/endometrial intraepithelial neoplasia (AEH/EIN) and early-stage endometrioid endometrial cancer (EEC), with particular emphasis on oncologic and reproductive outcomes. Methods: A systematic search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library was conducted from database inception through May 2026. Eligible studies included randomized controlled trials, prospective studies, and retrospective cohort studies evaluating metformin-containing fertility-sparing treatment regimens in women with AEH/EIN or early-stage EEC. Owing to substantial clinical and methodological heterogeneity in study design, treatment protocols, metformin dosage, follow-up duration, and outcome reporting, a quantitative meta-analysis was considered inappropriate, and the findings were synthesized narratively. Results: Eight publications represented approximately 795 unique patients after accounting for overlapping cohorts. Complete response was reported in 63/92 patients overall (69%) in Acosta-Torres et al., including 23/34 (68%) receiving progestin plus metformin, and in 61/63 (97%) receiving medroxyprogesterone acetate plus metformin in Mitsuhashi et al. Reported recurrence rates ranged from 13.1% to 34.2%. Live births occurred in 2/34 (6%) metformin-treated patients in Acosta-Torres et al., 14/31 (45%) women wished to conceive in Mitsuhashi et al., and 29/79 (36.7%) patients overall in Jing et al. Differences in populations, assessment times, and reproductive denominators limited direct comparisons and attribution of benefit to metformin. Conclusions: Current evidence suggests that metformin may have a promising adjunctive role in fertility-sparing treatment for women with AEH/EIN and early-stage EEC, particularly among patients with obesity, insulin resistance, polycystic ovary syndrome, or other metabolic risk factors. Nevertheless, the overall body of evidence should be interpreted with caution because of substantial heterogeneity across studies, the predominance of retrospective designs, and the limited number of prospective randomized trials. Well-designed multicenter randomized controlled trials are required to define the optimal role of metformin, identify the patients most likely to benefit, and establish standardized treatment strategies before routine incorporation into clinical practice can be recommended.

PMID 42882834
Read full article →
PubMedJournal of clinical medicine2026-10-16

Effects of Metformin on Clinical Outcomes After Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Chen Ting-Yen TY, Su Yu-Chi YC, Lin Yu-Ching YC

Objective: This study investigated the effects of metformin on clinical outcomes after acute ischemic stroke in patients with type 2 diabetes mellitus (T2DM). Methods: PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched for relevant English articles published from database inception to 6 April 2026. Moreover, the reference lists of eligible articles were searched. Studies were included if they focused on patients with T2DM and acute ischemic stroke, indicated whether the patients used metformin before stroke onset, and reported the patients' modified Rankin Scale (mRS) scores after stroke onset. Studies lacking adequate outcome data were excluded. Two reviewers independently extracted relevant data-for example, study details, clinicodemographic characteristics, and poststroke outcomes (mRS scores, National Institutes of Health Stroke Scale [NIHSS] scores, symptomatic intracranial hemorrhage [sICH], and mortality). A senior reviewer was consulted in cases of between-reviewer disagreements. The primary outcome was poststroke mRS score (functional outcome), and the secondary outcomes were poststroke NIHSS scores (neurological severity), sICH, and mortality. Results: Eleven studies met the inclusion criteria. Most studies reported better functional outcomes (mRS scores) and lower NIHSS scores for metformin users than for nonusers. Some studies indicated reduced rates of sICH and mortality among metformin users than among nonusers. Sensitivity analyses generally supported the benefits of metformin. Caution should be exercised when interpreting these findings because the results might have been influenced by variations in study designs, stroke classifications, and renal function reporting. Conclusions: In patients with T2DM, metformin may reduce stroke severity and improve poststroke functional outcomes. To the best of our knowledge, this meta-analysis is the first to investigate the association between metformin use and neurological severity, estimate adjusted ORs for favorable functional outcomes, and highlight publication bias on this topic.

PMID 42881994
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Correction: Yang et al. Molecular Mechanism of Metformin Regulating the Regeneration of Planarian Dugesia japonica Through miR-27b. Int. J. Mol. Sci. 2025, 26, 7092.

Yang Kexin K, Feng Minmin M, Zhang Chunmei C, Zhao Zelong Z et al.

In the original publication [...].

PMID 42884187
Read full article →
PubMedOncotarget2026-10-16

WIN-MTB-2024002 - WIN International Molecular Tumor Board: A 52-year-old female with unmeasurable Stage IIIc colon cancer.

El-Deiry Wafik S WS, Hernando-Calvo Alberto A, Magidi Shai S, Bresson Catherine C et al.

Copyright: © 2026 El-Deiry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Colorectal cancer (CRC) is a leading cause of cancer-related mortality, with a complex molecular profile that impacts tumor behavior and treatment response. This case report discusses a 52-year-old female diagnosed with Stage IIIc colon cancer, exhibiting KRAS, TP53, IDH1, and APC mutations, as well as a tumor microenvironment with high PD-L1 expression and elevated VEGFR1 and VEGFR3. Despite surgical resection and adjuvant treatment which included FOLFOX, FOLFIRI with bevacizumab and local radiation, the patient’s disease was difficult to track due to small, non-FDG-avid lymph nodes in the aortocaval region and persistent circulating tumor DNA (ctDNA). Following a review by an international Molecular Tumor Board (MTB), maintenance therapy options were discussed, including the personalized combinations of regorafenib, sulindac, and metformin, or fruquintinib, sulindac, and metformin, based on the patient’s molecular alterations. Alternatively, 5-FU with or without bevacizumab was suggested. In the event of relapse, the MTB recommended the combination of regorafenib, sulindac, and metformin, with the addition of trametinib and ivosidenib. The combination of regorafenib, ipilimumab, and nivolumab (RIN) was also considered due to the patient’s high PD-L1 expression. Further clinical trial options, such as pan-RAF inhibitors, NK cell agonists, and TAS-102 with bevacizumab, were also discussed. Additionally, the potential combination of PD-1 and TGFβ inhibitors was explored. This case underscores the critical role of molecular profiling in tailoring personalized treatment strategies for advanced CRC, providing novel avenues for managing recurrent disease, even in the absence of measurable disease.

PMID 42885719
Read full article →
PubMedPolymers2026-10-16

mPEG-b-PCL-Based Nanoformulations of Aziridine-Functionalized 1,3,5-Triazine Derivative for Cancer Treatment.

Bagaeva Irina I, Sinitsyna Ekaterina E, Zmitrichenko Yuliia Y, Tochilnikov Gregorii G et al.

Developing nanoformulations of antitumor drugs represents a critical priority in addressing key challenges of free drug administration such as low therapeutic efficacy, poor bioavailability, and severe side effects, including high systemic toxicity. In this study, mPEG-b-PCL block copolymers of different molecular weights were synthesized and applied to develop nanoformulations of the antitumor aziridine-functionalized 1,3,5-triazine derivative, dioxadet (DOD) via nanoprecipitation. The resulting DOD-loaded nanoparticles exhibited optimal characteristics for intravenous administration, and high encapsulation efficiency. The effect of mPEG-b-PCL molecular weight on drug encapsulation and release was investigated, and the results were elucidated through computational analysis of the molecular binding mechanism between DOD and PCL. Release profiles showed a sustained biphasic pattern. Determination of DOD concentration in blood of healthy rats indicated that the nanoformulation extended DOD's circulation time. The empty nanoparticles were well-tolerated by both normal and cancer cells. The nanoformulation maintained inhibitory activity against A549 cells with an IC50, comparable to that of free DOD. The antitumor efficacy and reduced toxicity of the optimized nanoformulation were demonstrated in mice using two ascitic tumor models (Ehrlich ascites carcinoma and L1210 lymphoid leukemia) and one solid tumor model (Lewis lung epidermoid carcinoma) with the greatest therapeutic effect observed against the solid tumor.

PMID 42885041
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about gemigliptin + metformin hydrochloride